Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination.
Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination.
复制标题
DOI：
10.1111/jdi.12151
复制
发表时间：
2014-05-04
影响因子：
3.2
通讯作者：
Araki E
中科院分区：
文献类型：
--
作者：
Shimoda S;Iwashita S;Sekigami T;Furukawa N;Matsuo Y;Ichimori S;Goto R;Maeda T;Watanabe E;Kondo T;Matsumura T;Motoshima H;Nishida K;Araki E
本研究的目的是在接受西格列汀和格列美脲联合治疗后血糖控制不佳的日本2型糖尿病患者中检查西格列汀剂量增加或格列美脲剂量增加的影响。在50例接受西格列汀和低剂量格列美脲治疗的2型糖尿病患者中开展了一项多中心、前瞻性、随机、开放标签研究。患者被随机分配接受50 mg/天西格列汀或0.5 mg/天格列美脲的额外治疗。主要终点是糖化血红蛋白（HbA 1c）的百分比变化。在随访期间，两组之间HbA 1c的百分比变化差异不显著（P = 0.13）。然而，HbA 1c随格列美脲剂量增加而显著降低（与基线相比P < 0.01），但随西格列汀剂量增加而不显著降低（P = 0.74）。单因素线性回归分析显示，两组中HbA 1c的百分比变化与血清花生四烯酸（AA）水平显著相关。两组之间的HbA 1c降低效应无显著差异。然而，发现格列美脲剂量增加对HbA 1c相对于基线有显著降低作用，西格列汀剂量增加组中AA水平与HbA 1c降低呈负相关，而格列美脲剂量增加组中AA水平与HbA 1c降低呈正相关。这些结果表明，在接受西格列汀和格列美脲联合治疗的2型糖尿病患者中，AA水平与这些药物剂量增加后HbA 1c降低相关。本试验已在UMIN注册（编号000009544）。
The goal of the study was to examine the effects of sitagliptin dose‐up or glimepiride dose‐up in Japanese patients with type 2 diabetes who were controlled inadequately by sitagliptin and glimepiride in combination. A multicenter, prospective, randomized, open‐label study was carried out in 50 patients with type 2 diabetes treated with sitagliptin and low‐dose glimepiride. The patients were randomly assigned to receive the addition of 50 mg/day sitagliptin or 0.5 mg/day glimepiride. The primary end‐point was the percentage change in glycated hemoglobin (HbA1c). During a follow‐up period, the difference in the percentage changes in HbA1c between the two groups was not significant (P = 0.13). However, HbA1c was significantly decreased by glimepiride dose‐up (P < 0.01 vs baseline), but not by sitagliptin dose‐up (P = 0.74). Univariate linear regression analyses showed that the percentage change in HbA1c was significantly associated with the serum level of arachidonic acid (AA) in both groups. There was no significant difference in the HbA1c‐lowering effects between the two groups. However, a significant HbA1c‐lowering effect from baseline of glimepiride dose‐up was found, and the AA level showed a negative correlation with the decrease in HbA1c in the sitagliptin dose‐up group, but a positive correlation in the glimepiride dose‐up group. These findings suggest that the AA level is associated with HbA1c reduction in response to dose‐up with these drugs in patients with type 2 diabetes in a combination therapy with sitagliptin and glimepiride. This trial was registered with UMIN (no. 000009544).
登录
查看更多内容
影响因子：
4.3
作者：
Cho, Young Sik;Kim, Chi Hyun;Cheon, Hyae Gyeong
通讯作者：
Cheon, Hyae Gyeong
影响因子：
2
作者：
Iwamoto, Yasuhiko;Taniguchi, Tadaaki;Amatruda, John
通讯作者：
Amatruda, John
影响因子：
15.9
作者：
ROBERTSON, RP;GAVARESKI, DJ;BIERMAN, EL
通讯作者：
BIERMAN, EL
影响因子：
5.8
作者：
Iwamoto, Y.;Tajima, N.;Amatruda, J. M.
通讯作者：
Amatruda, J. M.
影响因子：
5.8
作者：
Hermansen, K.;Kipnes, M.;Stein, P.
通讯作者：
Stein, P.